These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 16231271)
1. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Pancharoen C; Mekmullica J; Thisyakorn U; Kasempimolporn S; Wilde H; Herzog C Clin Infect Dis; 2005 Nov; 41(10):1537-40. PubMed ID: 16231271 [TBL] [Abstract][Full Text] [Related]
2. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. Frösner G; Steffen R; Herzog C J Travel Med; 2009; 16(6):413-9. PubMed ID: 19930383 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. D'Acremont V; Herzog C; Genton B J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593 [TBL] [Abstract][Full Text] [Related]
4. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Ambrosch F; Finkel B; Herzog C; Koren A; Kollaritsch H Infection; 2004 Jun; 32(3):149-52. PubMed ID: 15188074 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. Beck BR; Hatz CF; Loutan L; Steffen R J Travel Med; 2004; 11(4):201-6. PubMed ID: 15541221 [TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. Van Der Wielen M; Vertruyen A; Froesner G; Ibáñez R; Hunt M; Herzog C; Van Damme P Pediatr Infect Dis J; 2007 Aug; 26(8):705-10. PubMed ID: 17848882 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917 [TBL] [Abstract][Full Text] [Related]
10. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. Bovier PA; Bock J; Ebengo TF; Frösner G; Glaus J; Herzog C; Loutan L J Med Virol; 2010 Oct; 82(10):1629-34. PubMed ID: 20827757 [TBL] [Abstract][Full Text] [Related]
11. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W; J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896 [TBL] [Abstract][Full Text] [Related]
12. [The study on the 0, 12 month vaccination schedule' of Healive inactivated hepatitis A vaccine in children]. Ren YH; Chen JT; Wu WT; Gong XJ; Zhang YC; Xue WH; Ren YF; Han LJ; Kang WX; Li SP; Liu CB Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Nov; 24(11):1013-5. PubMed ID: 14687502 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years. Abarca K; Ibáñez I; de la Fuente P; Cerda L; Bergeret J; Frösner G; Ibarra H Vaccine; 2011 Nov; 29(48):8855-62. PubMed ID: 21983354 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. López EL; Contrini MM; Xifró MC; Cattaneo MA; Zambrano B; Dumas R; Rouyrre N; Weber F Vaccine; 2007 Jan; 25(1):102-8. PubMed ID: 16914234 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial. Jiang WP; Chen JT; Wang X; Wang YL; Liu Y; Chen WY; Xu WG; Qiu YZ; Yin WD Vaccine; 2008 Apr; 26(18):2297-301. PubMed ID: 18395305 [TBL] [Abstract][Full Text] [Related]
16. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Beck BR; Hatz C; Brönnimann R; Herzog C Clin Infect Dis; 2003 Nov; 37(9):e126-8. PubMed ID: 14557982 [TBL] [Abstract][Full Text] [Related]
17. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Bovier PA Expert Rev Vaccines; 2008 Oct; 7(8):1141-50. PubMed ID: 18844588 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India. Jain H; Kumavat V; Singh T; Versteilen A; Sarnecki M Hum Vaccin Immunother; 2014; 10(7):2089-97. PubMed ID: 25424821 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. Mayorga Pérez O; Herzog C; Zellmeyer M; Loáisiga A; Frösner G; Egger M J Infect Dis; 2003 Sep; 188(5):671-7. PubMed ID: 12934183 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. Saksawad R; Likitnukul S; Warachit B; Hanvivatvong O; Poovorawan Y; Puripokai P Vaccine; 2011 Jun; 29(29-30):4735-8. PubMed ID: 21570433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]